Jianxing Tang - 8Jiang Su Simcere Pharmaceutical Co., Ltd

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 11 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

Yan Xiao-hua, Ming Cheng,Xiaoling Shen,Siqi Zhao, Feng Tang,Jianxing Tang,Chunxia Ao, Xue Li,Shixin Zhu,Feng Wang,Wenqing Yang

Journal of pharmaceutical and pharmacological sciencesno. 1 (2024)

Cited0Views0Bibtex

SCR-7952, a Highly Selective MAT2A Inhibitor, Demonstrates Synergistic Antitumor Activities in Combination with the S-adenosylmethionine-competitive or the Methylthioadenosine-Cooperative Protein Arginine Methyltransferase 5 Inhibitors in Methylthioadenosine Phosphorylase-Deleted Tumors

Zhiyong Yu, Yi Kuang,Liting Xue,Xuan Ma, Tingting Li, Linlin Yuan, Mengying Li, Grace Xue, Zhen Li,Feng Tang,Jianxing Tang, Jinwen Shan,Weijie Wang,Renhong Tang, Feng Zhou

MEDCOMMno. 10 (2024)

Cited0Views0WOSBibtex

Abstract LB271: Synergistic Anti-Tumor Efficacy in Olaparib-Sensitive and -Resistant Models Via Simultaneously Inhibition of USP1 and PARP

Shuqun Yang,Zhengtao Li,Lei Zhou, Feng Zhou,Xiaokang Qin,Liting Xue, Piaopiao Xu,Jianxing Tang, Wendy Wang,Renhong Tang

Cancer Researchno. 7_Supplement (2024)

Cited0Views0Bibtex

Abstract P5-02-53: P95HER2 Expression in HER2-Positive Breast Cancer

Chih Wan Goh,Liyi Zhang,Wei-Ru Chi,Bingqiu Xiu,Jiajian Chen,Wenqing Yang,Chunxia Ao,Jianxing Tang,Jingyan Xue,Yayun Chi,Jiong Wu

Cancer researchno. 5_Supplement (2023): P5-53

Cited0Views0Bibtex

P95HER2 Expression in HER2-Positive Breast Cancer

Chih Wan Goh,Liyi Zhang,Wei-Ru Chi,Bingqiu Xiu,Jiajian Chen,Wenqing Yang,Chunxia Ao,Jianxing Tang,Jingyan Xue,Yayun Chi,Jiong Wu

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

Efficacy and Safety of SIM0417 (SSD8432) Plus Ritonavir for COVID-19 Treatment: a Randomised, Double-Blind, Placebo-Controlled, Phase 1b Trial

Fuxiang Wang, Wen Xiao,Yimin Tang,Mengli Cao,Dan Shu,Tetsuya Asakawa,Yechun Xu,Xiangrui Jiang,Leike Zhang,Wei Wang,Jianxing Tang, Yuansheng Huang, Yang,Yumei Yang,Renhong Tang,Jingshan Shen,Hongzhou Lu

The Lancet regional health Western Pacific (2023): 100835-100835

Cited2Views0WOSBibtex

Abstract P001: the Anti-Angiogenic Antibody BD0801 Demonstrates Better Anti-Tumor Activity Than Bevacizumab and Synergize with Chemotherapies in Multiple Tumor Models

Liting Xue,Jianxing Tang, Yuyin Ding, Lei Song,Shansen Xu,Yue Huang, Yan Wu,Wenjie Song,Renhong Tang,Wenqing Yang

Poster Presentations - Proffered Abstracts (2021)

Cited0Views0Bibtex

Antiangiogenic Antibody BD0801 Combined with Immune Checkpoint Inhibitors Achieves Synergistic Antitumor Activity and Affects the Tumor Microenvironment

Liting Xue,Xingyuan Gao,Haoyu Zhang,Jianxing Tang,Qian Wang,Feng Li, Xinxin Li,Xiaohong Yu,Zhihong Lu,Yue Huang,Renhong Tang,Wenqing Yang

BMC Cancer（2021）

Cited6Views0Bibtex

Abstract 4187: Preclinical Evaluation of Sulfatinib, a Novel Angio-Immuno Kinase Inhibitor Targeting VEGFR, FGFR1 and CSF1R Kinases

Jinghong Zhou,Jun Ni,Min Cheng,Na Yang,Junqing Liang, Liang Ge, Wei Zhang,Jianxing Tang,Qiaoling Sun, Fu Li,Jia Hu,Dongxia Shi,Hongbo Chen,Jingwen Long,Junen Sun,Fang Yin,Xuelei Ge,Hong Jia,Feng Zhou,Yongxin Ren,Weiguo Qing,Weiguo Su

Cancer researchno. 13_Supplement (2017): 4187-4187

Cited4Views0Bibtex

Abstract 2089: Evaluation of Fruquintinib, a Potent and Selective Oral VEGFR Inhibitor, in Combination with Targeted Therapies or Immune Checkpoint Inhibitors in Preclinical Tumor Models

Yongxin Ren,Qiaoling Sun,Jingwen Long,Shiming Fan,Renxiang Tang, Wei Zhang,Xuelei Ge,Jianxing Tang,Linfang Wang,Dongxia Shi,Hongbo Chen,Min Cheng,Weiguo Qing,Weiguo Su

Cancer research（2017）

Cited5Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn